Charged pyridinium oximes with thiocarboxamide moiety are equally or less effective reactivators of organophosphate-inhibited cholinesterases compared to analogous carboxamides

Zuzana Kohoutová, David Malinák, Rudolf Andryš, Jana Svobodová, Miroslav Psotha, Lukas Prchal, Monika Schmidt, Kamil Musilek, Zuzana Kohoutová, David Malinák, Rudolf Andryš, Lukas Prchal, Miroslav Psotha, Kamil Musilek

Faculty of Science, Department of Chemistry, University of Hradec Králové, Hradec Králové, Czech Republic; Biomedical Research Centre, University Hospital in Hradec Králové, Hradec Králové, Czech Republic

ABSTRACT
The organophosphorous antidotes, so-called oximes, are able to restore the enzymatic function of acetylcholinesterase (AChE) or butyrylcholinesterase (BChE) via cleavage of organophosphate from the active site of the phosphorylated enzyme. In this work, the charged pyridinium oximes containing thiocarboxamide moiety were designed, prepared and tested. Their stability and pKa properties were found to be analogous to parent carboxamides (K027, K048 and K203). The inhibitory ability of thiocarboxamides was found in low μM levels for AChE and high μM levels for BChE. Their reactivation properties were screened on human recombinant AChE and BChE inhibited by nerve agent surrogates and paraoxon. One thiocarboxamide was able to reactivate BChE inhibited by all tested organophosphates. These results were confirmed by reactivation kinetics, where thiocarboxamides were proved to be effective, but less potent reactivators if compared to carboxamides.

Introduction
Organophosphates (OP) widely used as pesticides (e.g. chlorpyrifos, parathion) are synthetically prepared compounds that can also be misused as chemical weapons (e.g. nerve agents sarin, soman, tabun, VX)1. They are stable, and have a rapid effect, primary in the nervous system, after being absorbed by the skin and respiratory system2,3. OP are irreversible inhibitors of ChEs, acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE, EC 3.1.1.8). While inhibition of AChE can lead to life threatening intoxication due to cholinergic overstimulation and crisis, inhibition of BChE has no direct adverse effects. For this reason, BChE can be used as the OP bioscavenger and it is considered as a pseudo-catalytic bioscavenger4. The mechanism of AChE inhibition implies rapid phosphorylation of the Ser203 hydroxyl site of the phosphylated enzyme. In this work, the charged pyridinium scaffold with oxime moiety was proposed from K027 (Figure 2) have been presented to be potent reactivators of OP-inhibited AChE in vitro or in vivo5,6. Based on the structure of the standard monoquaternary and bisquaternary reactivators, novel oxime were prepared, e.g. derivatives of 2-PAM or group of reactivators called ,,K-oximes5,7. Some of the K-oximes showed promising results in restoring activity of AChE inhibited by several OPs. I.e. K027 (5), K048 (6) and K203 (7) (Figure 2) have been presented to be potent reactivators of OP-inhibited AChE. For this reason, the molecular design of charged pyridinium oximes with thiocarboxamide moiety was proposed from K027 (5), K048 (6) and K203 (7). The pyridinium scaffold with oxime moiety was retained as the α-nucleophile that is able to attack OP-inhibited cholinesterase. Similarly, the second aromatic moiety and the connecting linker remained to be same as in the parent molecules. Differently, the carboxamide moiety was replaced by thiocarboxamide. Using the spatially bulkier thiocarboxamide, the peripheral site of AChE5,7 was retained as the α-nucleophile that is able to attack OP-inhibited cholinesterase.
and overall affinity towards particular cholinesterase or it could increase the affinity to OP-enzyme complex for better reactivation.

In this work, the novel bis-pyridinium oximes were designed, synthesised and evaluated. The stability, oximate formation properties, inhibition of human ChEs and reactivation of human OP-inhibited ChEs was studied.

**Experimental**

**Chemistry**

All chemicals used for the synthesis were purchased from Sigma-Aldrich (Prague, Czech Republic) in the highest available purity. All used solvents were supplied by Penta Chemicals Unlimited (Prague, Czech Republic). Organophosphorus compounds 4-nitrophenyl isopropanol methylphosphonate (NIMP, sarin surrogate), 4-nitrophenyl ethyl methylphosphonate (NEMP, VX surrogate), 4-nitrophenyl ethyl dimethylphosphoramidate (NEDPA, tabun surrogate) and paraoxon (POX) were purchased from Chemforase (Mont-Saint-Aignan, France). Thin layer chromatography was performed on Merck silica gel 60 F254 and Merck cellulose F analytical plates. Detection was carried out with ultraviolet light (254 nm). Melting points were recorded on a Melting Point Apparatus - Büchi B-545 (Donau Lab, Czech Republic) without correction. The \(^1\)H and \(^{13}\)C NMR spectra were measured in DMSO-d\(_6\) solution at room temperature on FT NMR spectrometer Avance NEO 500 MHz (499.87 MHz for \(^1\)H and 125.71 MHz for \(^{13}\)C) (Bruker, Germany).

Chemical shifts, \(\delta\), are given in parts per million (ppm) and spin multiplicities are given as br s (broad singlet), s (singlet), d (doublet) or m (multiplet). Coupling constants, \(J\), are expressed in hertz (Hz). For \(^1\)H \(\delta\) is relative to DMSO-d\(_6\) (\(\delta = 2.50\)) and for \(^{13}\)C \(\delta\) is relative to DMSO-d\(_6\) (\(\delta = 39.43\)). High Resolution Mass Spectrometry (HRMS) was determined by Q-Exactive Plus hybrid quadrupole-orbitrap spectrometer.

**General procedure for synthesis of monoquaternary salts 8–10**

The monoquaternary salts 8–9 were prepared by reaction of 4-hydroxyethylpyridine (32.8 mM) and dibromoalkane (163.8 mM) in acetonitrile (30 ml). The mixture was stirred at reflux for 8 h, then cooled to room temperature and filtered and washed with acetonitrile (3 × 30 ml). The crude product was recrystallised from acetonitrile.

The monoquaternary salt 10 was prepared by reaction of 4-hydroxyethylpyridine (8.20 mM) and \((E)-1,4\)-dibromophe-2-ene (40.90 mM) in acetonitrile (30 ml). The mixture was stirred at reflux for 1.5 h, then cooled to room temperature and crystalline crude product was collected by filtration, washed with acetonitrile (2 × 30 ml). The product was recrystallised from acetonitrile.

**General procedure for synthesis of bisquaternary salts 11–13**

Secondly, the synthesis of the bisquaternary salt was completed. To a solution of monoquaternary salt 8–10 (1.48 mM) in

---

Figure 1. Structure of commercially available oxime reactivators.

Figure 2. Structure of K027 (5), K048 (6) and K203 (7).
dimethylformamide (DMF, 1.40 ml) was added 4-pyrindinethioamide (2.22 mM). The resulting mixture was stirred at 60 °C for 48 h. The solvent was concentrated under the reduced pressure and the crude product was purified by crystallisation from acetonitrile at reflux. Then the solid was filtered, washed with acetonitrile and dried under the vacuum.

4-Carbamothioyl-1-(3-(4-(hydroxyimino)methyl)pyridinium-1-yl) propyl)pyridinium dibromide (11) K487

Compound 11 was isolated as orange solid, yield 245 mg (36%), m.p. 127.1–129.1 °C. 1H NMR (500 MHz, DMSO-d6): δ 2.65–2.71 (m, 2H, CH2, 4.75–4.80 (m, 4H, 2 × CH2), 8.28 (d, J = 6.1 Hz, 2H, 2 × ArH), 8.34 (d, J = 6.1 Hz, 2H, 2 × ArH), 8.47 (s, 1H, CH), 9.13 (d, J = 6.0 Hz, 2H, 2 × ArH), 9.24 (d, J = 6.1 Hz, 2H, 2 × ArH), 10.29 (br s, 1H, NH), 10.74 (br s, 1H, NH), 12.85 (s, 1H, OH). 13C NMR (126 MHz, DMSO-d6): δ 31.4, 56.9, 57.2, 124.1, 124.9, 145.0, 145.1, 145.4, 148.5, 152.5, 194.1. HRMS (ESI+): [M + H]+: calculated for C16H18N4OS2: 315.10595; found: 315.10594.

4-Carbamothioyl-1-(4-(4-(butyl)pyridinium-1-yl) methyl)pyridinium dibromide (12) K488

Compound 12 was isolated as orange solid, yield 364 mg (52%), m.p. 180.3–182.3 °C. 1H NMR (500 MHz, DMSO-d6): δ 1.96–2.02 (m, 4H, 2 × CH2), 4.67–4.76 (m, 4H, 2 × CH2), 8.25 (d, J = 6.3 Hz, 2H, 2 × ArH), 8.31 (d, J = 6.4 Hz, 2H, 2 × ArH), 8.45 (s, 1H, CH), 9.14 (d, J = 6.4 Hz, 2H, 2 × ArH), 9.25 (d, J = 6.4 Hz, 2H, 2 × ArH), 10.29 (br s, 1H, NH), 10.72 (br s, 1H, NH), 12.81 (s, 1H, OH). 13C NMR (126 MHz, DMSO-d6): δ 26.9, 27.0, 59.2, 59.5, 124.0, 124.9, 145.0, 145.2, 148.3, 152.4, 194.2. HRMS (ESI+): [M + H]+: calculated for C18H20N4O2S2: 327.10567; found: 327.10563.

4-Carbamothioyl-1-(4-(4-(IE)-(hydroxyimino)methyl)pyridinium-1-yl)but-2-ene-1-yl)pyridinium dibromide (13) K489

Compound 13 was isolated as orange solid, yield 431 mg (61%), m.p. 199.1–201.1 °C. 1H NMR (500 MHz, DMSO-d6): δ 5.35–5.39 (m, 4H, 2 × CH2), 6.17–6.30 (m, 2H, 2 × CH), 8.27 (d, J = 6.7 Hz, 2H, 2 × ArH), 8.32 (d, J = 6.8 Hz, 2H, 2 × ArH), 8.46 (s, 1H, CH), 9.06 (d, J = 6.7 Hz, 2H, 2 × ArH), 9.17 (d, J = 6.8 Hz, 2H, 2 × ArH), 10.34 (br s, 1H, NH), 10.75 (br s, 1H, NH), 12.87 (s, 1H, OH). 13C NMR (126 MHz, DMSO-d6): δ 60.3, 60.6, 124.0, 124.9, 129.6, 130.6, 145.0, 145.1, 145.3, 148.7, 152.9, 194.2. HRMS (ESI+): [M + H]+: calculated for C16H16N6O2S2: 317.10595; found: 317.10594.

Stability determination

The stability of tested compounds was evaluated in two different media – demineralised water and phosphate buffered saline (PBS; Sigma-Aldrich P4417) as simulation of physiological environment. Compounds were dissolved in particular solvent (final concentration 1 mg/mL) and incubated at 37 °C. The amounts of analysed compounds were determined at time intervals of 0, 1, 2, 3, 4 and 5 h by UHPLC Infinity II 1290 system (Agilent Technologies, Santa Clara, USA) coupled with DAD detector. The stability was evaluated as the amount of remaining compound (%) in sample after specific time interval. GraphPad Prism version 8.2 (San Diego, USA) was used for the statistical data evaluation and visualisation.

pKd determination

The negative decimal logarithms of the dissociation constants (pKd) of prepared compounds were determined spectrophotometrically using buffers of given pH (range from 4.5 to 10.0 with 0.5 unit increment). Ten microliters of tested oxime (1 mg/mL) were dissolved in 490 μL of particular buffer and absorbance spectra of various dissociation states were scanned in range 200–400 nm using Carry-60 UV-VIS spectrophotometer (Agilent Technologies, Santa Clara, USA) at 20 °C. The pKd values were calculated from the sigmoidal dependence of the absorbance of the dissociated form of the substance on the pH value using GraphPad Prism 8.2 software (San Diego, USA).

Inhibition assay

Recombinant forms of human acetylcholinesterase (hrAChE) and butyrylcholinesterase (hrBChE) were prepared at the Department of Chemistry, Faculty of Science, University of Hradec Kralove. The inhibitory effect of tested oximes on hrAChE/hrBChE was determined by standard Ellman method adapted for 96-well plates. The reaction mixture consists of hrAChE (final protein concentration 70 ng/mL) or hrBChE (220 ng/mL of protein), water solution of tested compound at appropriate concentration (the range of 1 μM to 500 μM for hrAChE and of 50 μM to 150 μM for hrBChE) and solution of 5,5'-dithiobis-2-nitrobenzoic acid (DTNB, final concentration 500 μM, pH 7.4) in 20 mM Na-phosphate buffer. The mixture was pre-incubated for 15 min at 37 °C. Afterwards the substrate acetylthiocholine iodide (ATCI) or butyrylthiocholine iodide (BTCI) was added to the final concentration of 100 μM. The total volume of reaction was 100 μL. Creation of the product 5-thio-2-nitrobenzoic acid (TNB), formed during the reaction was determined by observing its absorbance at specific wavelength 436 nm. The catalytic activity of enzyme was evaluated as amount of product (%) formed in the reaction after 10 min of incubation at 37 °C. IC50 values of compounds were calculated using non-linear regression by GraphPad Prism 8.2 (San Diego, USA). Data were calculated from three individual experiments which were made in triplicate.

Reactivation screening

Recombinant enzymes (hrAChE/hrBChE) were inhibited by 25 μM POX, NEMP, NIMPor NEDPA for 30 min to obtain >99% inhibition. The excess of organophosphate was removed by dialysis against 25 mM Na-phosphate buffer (pH 7.4) for 16 h with three buffer exchanges. The tested oxime (10 μM or 100 μM) was incubated with inhibited enzyme for 15 or 30 min at 37 °C. The reaction mixture (100 μL) contained 10 μL of inhibited enzyme (1.95 ng of total protein), 20 μL of DTNB (2.5 mM), 10 μL of relevant oxime solution and 50 μL of Na-phosphate buffer (25 mM, pH 7.4). In parallel, reaction mixture containing no enzyme was followed as blank reaction to reflect oximolysis. The reaction was started by addition of 10 μL of substrate ATCI or BTCI (10 mM). The catalytic activity of enzyme reactivated by oxime was determined spectrophotometrically at specific wavelength 436 nm using Spark multimode microplate reader Tecan (Mannedorf, Switzerland). Data were calculated from three individual experiments which were made in triplicate.

Reactivation kinetics

The selected compounds with promising reactivation ability were further tested to investigate reactivation kinetics parameters. Inhibited enzyme (hrAChE/hrBChE) was incubated for eight different times (0.5 to 15 min) with seven different concentrations of tested oxime (varying from 1 to 1200 μM) at 37 °C. As the blank the mixture containing no enzyme (to control oximolysis) was used. Acquired data were analysed by non-linear regression analysis according to Worek et al. using GraphPad Prism 8.2. Data were calculated from three individual experiments which were made in triplicate.
Results and discussion

Chemical synthesis

The monoquaternary precursors 8–10 were formerly prepared by our research group\textsuperscript{23–25}. Subsequent bimolecular nucleophilic substitution (SN\textsubscript{2}) of these monoquaternary salts with 4-pyridinethioamide in aprotic polar solvent DMF allowed creation of bisquaternary salts 11–13 (Scheme 1). The yields of these reactions ranged from 36\% to 61\%. The lowest yield was obtained in case of compound 11 (K487) which was probably caused by steric hindrance of two close pyridinium rings. The highest yield was obtained for compound 13 (K489), which contains but-2-en-1,4-diy chain. In this case, the substrate 10 react rapidly by the SN\textsubscript{2} mechanism because the $\pi$-system of the adjacent double bond can stabilise the transition state by conjugation. The final compounds were determined by NMR (Supplementary Figures 1–6) and HRMS analysis. Based on NMR and HRMS analysis, the non-calibrated purity of all products was $\geq$95\%.

Stability determination

Prepared compounds K487 (11), K488 (12) and K489 (13) and analogous oximes K027 (5), K048 (6) and K203 (7) were tested for stability in unionised water and PBS at 37°C for 5 h, when the buffered environment and selected temperature are better mimicking human relevant conditions and the selected time is close to a full elimination of similar oximes from human organism. All compounds showed high stability in both media after 5 h (Figure 3). The degradation of tested oximes in pure water was found negligible. Some degradation of K489 (13) and K203 (7) was found in PBS buffer, but still with residual >90\% oxime after 5 h. Stability is very important parameter for the compound use and also for maintaining the biological activity for the necessary time i.e. first 1–2 h after OP intoxication for charged oximes\textsuperscript{29}.

$\text{pK}_a$ determination

The $\text{pK}_a$ values were determined for compounds K487 (11), K488 (12), K489 (13), pralidoxime (1), asoxime (4) and for parent oximes (5–7). The $\text{pK}_a$ is an important parameter in pharmaceutical development to rationalise the physicochemical and biopharmaceutical properties of the drug molecule. It allows to detect protonated/deprotonated form of the compound under physiological conditions. In case of oximes deprotonated form so called oximate anion is important, because it is the active form of the oxime reactivator\textsuperscript{30}. Change of amide group into thioamide group did not caused significant changes in the $\text{pK}_a$ values of oxime moiety (Table 1). This result was expected because sulphur does not differ much in electronegativity compared to oxygen. Moreover, thiocarbamoyl moiety is far distanced to affect the electron density at the oxime pyridinium ring.

In vitro enzyme inhibition

All novel compounds 11–13 (K487–K489) and oximes K027 (5), K048 (6), K203 (7), pralidoxime (1) and asoxime (4) were tested for in vitro inhibition of hrAChE and hrBChE. While standard and parent oximes resulted as poor AChE and BChE inhibitors,
compounds K487 (11), K488 (12) and K489 (13) resulted as relatively stronger inhibitors of both enzymes (Figure 4). The inhibition of hrAChE was found to be relatively higher in low μM scale (IC$_{50}$ 7–16 μM), while inhibition of hrBChE resulted to be relatively lower in high μM scale (IC$_{50}$ 189–320 μM). Oxime K488 (12) was found to be the most potent hrAChE (IC$_{50}$ 7 μM) and hrBChE (IC$_{50}$ 189 μM) inhibitor. This increase of inhibitory ability is most probably caused by sulphur atom. Although we did not study particular interaction with ChEs active sites, we suppose that bulkier sulphur atom has different binding and interactions at the active site gorge (e.g. hydrogen bonding properties) i.e. the sulphur atom is probably occupying more space within the peripheral site of the active site of AChE, which leads to stronger interactions with present aromatic amino acids and consequently increases the compound’s inhibition potency. The inhibition of BChE was less pronounced since BChE has less aromatic amino acids in its active site.

**In vitro reactivation screening**

All compounds were screened for reactivation ability on both ChEs inhibited by nerve agent surrogates NIMP, NEMP, NEDPA and POX as a representative of OP pesticides. The reactivation

![Figure 4. Inhibitory effect of tested compounds on hrAChE (A) and hrBChE (B).](image)

![Figure 5. Reactivation of hrAChE inhibited by OP surrogates (%) with 10 μM oximes 11–13 after 15 min at 37 °C. Results were compared to pralidoxime (1), asoxime (4) and parent oximes (5–7).](image)
of OP-inhibited AChE was screened with 10 μM concentration of oxime after 15 min (Figure 5, Supplementary Table 2). For NIMP-AChE, the best reactivation was obtained for 6 (~73%) followed by asoxime (4, ~44%). Generally, the thiocarboxamides (11–13) were found as less potent reactivators when compared to carboxamide analogues (5–7). For NEMP-AChE, the best reactivation was observed with carboxamides (5–7, ~46–61%) followed by thiocarboxamide K487 (11, ~31%). The NEDPA-inhibited AChE was well reactivated by carboxamides (5–7, ~51–60%) and thiocarboxamide K487 (11, ~47%). The tested oximes were found to be poor reactivators of POX-inhibited AChE, and only K203 (7, ~30%) was able to restore AChE activity to some extent.

Taken together, pralidoxime (1) and asoxime (4) were found to be generally less potent reactivators of NEMP-, NEDPA- and POX-inhibited AChE, when compared to carboxamides (5–7), while thiocarboxamides (11–13) resulted as weaker reactivators if compared to carboxamides. This result is most probably related to the stronger inhibition of AChE provided by thiocarboxamides which decreases overall activity of reactivated enzyme.

The reactivation of OP-inhibited BChE was screened with 100 μM concentration of oxime after 15 min (Figure 6, Supplementary Table 3). In case of NIMP-BChE conjugate, carboxamides (5–7, ~74–82%) were found as the best reactivators followed by thiocarboxamides (11–12, ~53–57%) and pralidoxime (1, ~56%). The most potent reactivators of NEMP-BChE conjugate were carboxamides (5–7, ~38–41%) and thiocarboxamide 12 (~37%) which was found to be the most potent reactivator of NEDPA-BChE as well. Surprisingly for NEDPA, thiocarboxamide 12 (~25%) showed the best reactivation followed by carboxamides (5–7, ~16–18%). The POX-BChE was reactivated almost equally by carboxamides (5–7, ~27–34%) and thiocarboxamide 12 (~31%). Taken together, pralidoxime (1) and asoxime (4) were found to be generally less potent reactivators of NIMP-, NEMP-, NEDPA- and POX-inhibited BChE, when compared to carboxamides (5–7) and equally or slightly less effective thiocarboxamide 12. The better reactivation profile of thiocarboxamide 12 in case of BChE is pH-dependent.
related to the lower intrinsic inhibition of BChE and thus the overall higher activity of reactivated enzyme.

**Reactivation kinetics**

For reactivation kinetics, only few thiocarboxamides with promising reactivation screening parameters were selected and their carboxamide analogues were chosen for comparison. Compound 11 was chosen for kinetic experiments in case of NEDPA-inhibited AChE, due to its highest reactivation ability in the screening and compounds 11–12 were selected in case of NIMP-inhibited BChE.

The affinity of relevant oxime towards OP-inhibited recombinant enzyme (reflected by $K_\text{d}$) and the ability to remove the OP residue from the active site of the enzyme (reflected by $k_r$) were determined. Afterwards, the specific overall second-order reactivation rate constant ($k_{r2} = k_r/K_\text{d}$) was calculated. The highest affinity for NEDPA-inhibited AChE, as well as the fastest dephosphorylation of catalytic serine ($k_r$) was exhibited by oxime K027 (5), which therefore resulted with the highest $k_{r2}$ constant. Thiocarboxamide 11 was found to be a better reactivator of NEDPA-AChE than 2-PAM (1) and asoxime (4), but less effective than K027 (5) (Table 2). In addition, the reactivation kinetics of 5 and 11 towards NEDPA-AChE was directly compared by using 50 μM concentration of the reactivator (Figure 7). In this case, oxime 11 showed markedly lower reactivation which is caused by its higher inhibition of AChE ($IC_{50} \approx 10 $ μM), which indicates more convenient use of carboxamide moiety instead of thiocarboxamide one when using the same (trimethylene) linker.

NIMP-BChE conjugate showed the highest affinity for oxime K027 (5) and its analogue thiocarboxamide 11. Furthermore, due to the high reactivation rate ($k_r$) these oximes can be singled out as the best reactivators of NIMP-inhibited BChE with an overall reactivation rate of about 6-fold higher than 2-PAM and HI-6 (Table 2). The reactivation kinetics of 5 and 11 towards NIMP-BChE was also directly compared by using 100 μM concentration of the reactivator (Figure 7). Oxime 11 resulted as slightly weaker reactivator to its carboxamide analogue 5 which is again related to its slightly stronger inhibition of BChE.

The change of carboxamide into thiocarboxamide moiety doesn’t bring much benefit for reactivation of organophosphates and the presence of thiocarboxamide group causes unwanted higher inhibition of AChE/BChE and thus decreased reactivation.

**Conclusion**

Three pyridinium mono-oximes containing thiocarboxamide group were designed, synthesised and tested. The novel compounds were evaluated for stability, and all compounds resulted as highly stable in both media (water and PBS). Further, $pK_a$ was determined and compared to parent oximes or standard compounds and no significant changes in the $pK_a$ values were found. The inhibitory effect of tested compounds on hrAChE and hrBChE was tested, and the determined $IC_{50}$s were in the low μM range for hrAChE unlike for hrBChE. The novel compounds were evaluated for reactivation of hrAChE and hrBChE inhibited by NIMP (sarin-surrogate), NEMP (VX-surrogate), NEDPA (tabun-surrogate) and paraxoxon. From reactivation screening, compound K487 (11) showed ability to reactivate AChE inhibited by NEMP and NEDPA. For BChE screening, K487 (11) and K488 (12) were found to have ability to reactivate all tested OPs. The reactivation kinetics was further determined for thiocarboxamides K487 (11) and K488 (12). Oxime 11 resulted as slightly weaker reactivator of NEDPA-AChE or NIMP-BChE if compared to its direct carboxamide analogue 5, which is caused by its higher intrinsic inhibitory ability for both enzymes. Taken together, the tested thiocarboxamides resulted as equally or less effective charged oxime reactivators when compared to their carboxamide analogues. Therefore, the introduction of thiocarboxamide moiety doesn’t bring much benefit to the overall cholinesterase reactivation.

**Acknowledgements**

The authors are grateful to Hana Kaszperova, Bc. Radka Mikesova and Nicola Paulovicova for their skilful technical assistance.

**Disclosure statement**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

**Funding**

This work was supported by Czech Science Foundation [no. GA21-030005] and University of Hradec Kralove [Faculty of Science, no. SV2104-2021, VT2019-2021].

**ORCID**

Zuzana Kohoutova [http://orcid.org/0000-0003-3382-3997]
David Malinak [http://orcid.org/0000-0002-0665-0667]
Rudolf Andrys [http://orcid.org/0000-0003-1108-3924]
Jana Svobodova [http://orcid.org/0000-0001-7754-4231]
Miroslav Psotka [http://orcid.org/0000-0002-7857-7411]
Monika Schmidt [http://orcid.org/0000-0003-4984-9155]
Lukas Prchal [http://orcid.org/0000-0001-9698-4478]
Kamil Musilek [http://orcid.org/0000-0002-7504-4062]
References

1. Weerasinghe M, Pearson M, Konradsen F, et al. Emerging pesticides responsible for suicide in rural Sri Lanka following the 2008-2014 pesticide bans. BMC Public Health 2020;20:780.

2. Hrabetz H, Thiermann H, Felgenhauer N, et al. Organophosphate poisoning in the developed world - a single centre experience from here to the millennium. Chem Biol Interact 2013;206:561–8.

3. Amend N, Niessen KV, Seeger T, et al. Diagnostics and treatment of nerve agent poisoning-current status and future developments. Ann N Y Acad Sci 2020;1479:13–28.

4. Goldsmith M, Ashani Y. Catalytic bioscavengers as countermeasures against organophosphate nerve agents. Chem Biol Interact 2018;292:50–64.

5. Marrs TC. Organophosphate poisoning. Pharmac. Ther 1993;58:51–66.

6. Munro N. Toxicity of the organophosphate chemical warfare agents GA, GB, and VX: implications for public protection. Environ Health Perspect 1994;102:18–37.

7. Franjesevic AJ, Sillart SB, Beck JM, et al. Resurrection and reactivation of acetylcholinesterase and butyrylcholinesterase. Chemistry 2019;25:5337–71.

8. Hrvat NM, Kovarik Z. Counteracting poisoning with chemical warfare nerve agents. Arh Hig Rada Toksikol 2020;71:266–84.

9. Malinak D, Korabecny J, Soukup O, et al. A review of the synthesis of quaternary acetylcholinesterase reactivators. Curr. Org. Chem 2018;22:1619–48.

10. Yerri J, Dias J, Nimmakayala MR, et al. Chemoselective hydrogenation of 6-alkynyl-3-fluoro-2-pyridalidoximes: access to first-in-class 6-alkyl-3-fluoro-2-pyridalidoxime scaffolds as new reactivators of sarin-inhibited human acetylcholinesterase with increased blood-brain barrier permeability. Chem. Eur. J 2020;26:15035–44.

11. Zorbaz T, Malinak D, Maraković N, et al. Pyridinium oximes with ortho-positioned chlorine moiety exhibit improved physicochemical properties and efficient reactivation of human acetylcholinesterase inhibited by several nerve agents. J. Med. Chem 2018;61:10753–66.

12. Mercey G, Verdelet T, Renou J, et al. Reactivators of acetylcholinesterase inhibited by organophosphorus nerve agents. Acc Chem Res 2012;45:756–66.

13. Chambers JE, Dail MB, Meek EC. Oxime-mediated reactivation of organophosphate-inhibited acetylcholinesterase with emphasis on centrally-active oximes. Neuropharmacology 2020;175:108201.

14. Kuča K, Bielavský J, Cabal J, et al. Synthesis of a potential reactivator of acetylcholinesterase—1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium)propane dibromide. Tetrahedron Lett 2003;44:3123–5.

15. Kuča K, Bielavský J, Cabal J, et al. Synthesis of a new reactivator (l) of tabun-inhibited acetylcholinesterase. Bioorg. Med. Chem. Lett 2003;20:3545–7.

16. Musilek K, Jun D, Cabal J, et. al. Design of a potent reactivator of tabun-inhibited acetylcholinesterase-synthesis and evaluation of (E)-1-(4-carbamoylpyridinium)-4-(4-hydroxyimino- methylpyridinium)-but-2-ene dibromide (K203). J Med Chem 2007;50:5514–8.

17. de Castro AA, Assis LC, Soares FV, et al. Trends in the recent patent literature on cholinesterase reactivators (2016–2019). Biomolecules 2020;10:436.

18. Čalić M, Vrdoljak AL, Radić B, et al. In vitro and in vivo evaluation of pyridinium oximes: mode of interaction with acetylcholinesterase, effect on tabun- and soman-poisoned mice and their cytotoxicity. Toxicology 2006;219:85–96.

19. Kuča K, Musilek K, Jun D, et al. A newly developed oxime K203 is the most effective reactivator of tabun-inhibited acetylcholinesterase. BMC Pharmacology and Toxicology 2018;19:8.

20. Kassa J, Karasová Z, Krejčiová JM. Therapeutic efficacy of a novel bispyridinium oxime K203 and commonly used oximes (HI-6, obidoxime, trimedoxime, methoxime) in soman-poisoned male rats and mice. J. Appl. Biomed 2013;11:7–13.

21. Petroianu GA, Hasan MY, Nurulain SM, et al. New K-oximes (K-27 and K-48) in comparison with obidoxime (LuH-6), HI-6, trimedoxime (TMB-4), and pralidoxime (2-PAM): survival in rats exposed IP to the organophosphate paraoxon. Toxicol. Mech. Methods 2007;17:401–8.

22. Musilek K, Holas O, Misik J, et al. Mono-oxime-monocarboxymethyl bispyridinium xylene-linked reactivators of acetylcholinesterase-synthesis, in vitro and toxicity evaluation, and docking studies. ChemMedChem 2010;5:247–54.

23. Musilek K, Komloova M, Holas O, et al. Mono-oxime bisquinary acetylcholinesterase reactivators with prop-1,3-diyil linkage—preparation, in vitro screening and molecular docking. Bioorg. Med. Chem 2011;19:754–62.

24. Malinak D, Nepovimova E, Jun D, et al. Novel group of AChE reactivators—synthesis, in vitro reactivation and molecular docking study. Molecules 2018;23:2291.

25. Musilek K, Kuca K, Jun D, et al. Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase. Bioorg. Med. Chem. Lett 2006;16:622–7.

26. Pachon-Angona I, Refouelet B, Andrys R, et al. Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy. J Enzyme Inhib Med Chem 2019;34:479–89.

27. Ellman GL, Courtney KD, Andres V, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.

28. Worek F, van der Wellen J, Musilek K, et al. Reactivation kinetics of a homologous series of bispyridinium bis-oximes with nerve agent-inhibited human acetylcholinesterase. Arch Toxicol 2012;86:1379–86.

29. Handl J, Malinak D, Capek J, et al. Effects of charged oxime reactivators on the HK-2 cell line in renal toxicity screening. Chem Res Toxicol 2021;34:699–703.

30. Dohoda D, Tisman K, Tisman O, et al. Spectrophotometric pKa determination of ionizable pharmaceuticals: resolution of molecules with weak pH-dependent spectral shift. Journal of Pharmaceutical and Biomedical Analysis 2015;114:88–96.

31. Meek EC, Chambers HW, Coban A, et al. Synthesis and in vitro and in vivo inhibition potencies of highly relevant nerve agent surrogates. Toxicol Sci 2012;126:525–33.

32. Čadež T, Količ D, Šinko G, et al. Assesments of four organophosphorus pesticides as inhibitors of human acetylcholinesterase and butyrylcholinesterase. Sci. Rep 2021;11:21486.

33. Malinak D, Doležal R, Heparova V, et al. Synthesis, in vitro screening and molecular docking of isoquinolinium-5-carboxylic acids as acetylcholinesterase and butyrylcholinesterase reactivators. J Enzyme Inhib Med Chem 2020;35:478–88.

34. Winter M, Wille T, Musilek K, et al. Investigation of the reactivation kinetics of a large series of bispyridinium oximes with organophosphate-inhibited human acetylcholinesterase. Toxicol Lett 2016;244:136–42.